Alexander McGirr1, Marcelo T Berlim2, David J Bond3, Nicholas H Neufeld4, Peter Y Chan5, Lakshmi N Yatham6, Raymond W Lam7. 1. Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. Electronic address: alexander.mcgirr@alumni.ubc.ca. 2. Neuromodulation Research Clinic, Douglas Mental Health University Institute and McGill University, Montréal, Québec, Canada; Depressive Disorders Program, Douglas Mental Health University Institute and McGill University, Montréal, Québec, Canada. 3. Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA. 4. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 5. Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; Neurostimulation Service, Vancouver General Hospital, Vancouver, BC, Canada. 6. Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, BC, Canada. 7. Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, BC, Canada.
Abstract
BACKGROUND: Electroconvulsive therapy (ECT) remains one of the most effective tools in the psychiatric treatment armamentarium, particularly for refractory depression. Yet, there remains a subset of patients who do not respond to ECT or for whom clinically adequate seizures cannot be elicited, for whom ketamine has emerged as a putative augmentation agent. METHODS: We searched EMBASE, PsycINFO, CENTRAL, and MEDLINE from 1962 to April 2014 to identify randomized controlled trials evaluating ketamine in ECT (PROSPERO #CRD42014009035). Clinical remission, response, and change in depressive symptom scores were extracted by two independent raters. Adverse events were recorded. Drop-outs were assessed as a proxy for acceptability. Meta-analyses employed a random effects model. RESULTS: Data were synthesized from 5 RCTs, representing a total of 182 patients with major depressive episodes (n = 165 Major Depressive Disorder, n = 17 Bipolar Disorder). ECT with ketamine augmentation was not associated with higher rates of clinical remission (Risk Difference (RD) = 0.00; 95%CI = -0.08 to 0.10), response (RD = -0.01; 95%CI = -0.11 to 0.08), or improvements in depressive symptoms (SMD = 0.38; 95%CI = -0.41 to 1.17). Ketamine augmentation was associated with higher rates of confusion/disorientation/prolonged delirium (OR = 6.59, 95%CI: 1.28-33.82, NNH = 3), but not agitation, hypertension or affective switches. CONCLUSION: Our meta-analysis of randomized controlled trials of ketamine augmentation in the ECT setting suggests a lack of clinical efficacy, and an increased likelihood of confusion. Individuals for whom adequate seizures or therapeutic response cannot be obtained have not been studied using randomized controlled designs. Additional research is required to address the role of ketamine in this population.
BACKGROUND: Electroconvulsive therapy (ECT) remains one of the most effective tools in the psychiatric treatment armamentarium, particularly for refractory depression. Yet, there remains a subset of patients who do not respond to ECT or for whom clinically adequate seizures cannot be elicited, for whom ketamine has emerged as a putative augmentation agent. METHODS: We searched EMBASE, PsycINFO, CENTRAL, and MEDLINE from 1962 to April 2014 to identify randomized controlled trials evaluating ketamine in ECT (PROSPERO #CRD42014009035). Clinical remission, response, and change in depressive symptom scores were extracted by two independent raters. Adverse events were recorded. Drop-outs were assessed as a proxy for acceptability. Meta-analyses employed a random effects model. RESULTS: Data were synthesized from 5 RCTs, representing a total of 182 patients with major depressive episodes (n = 165 Major Depressive Disorder, n = 17 Bipolar Disorder). ECT with ketamine augmentation was not associated with higher rates of clinical remission (Risk Difference (RD) = 0.00; 95%CI = -0.08 to 0.10), response (RD = -0.01; 95%CI = -0.11 to 0.08), or improvements in depressive symptoms (SMD = 0.38; 95%CI = -0.41 to 1.17). Ketamine augmentation was associated with higher rates of confusion/disorientation/prolonged delirium (OR = 6.59, 95%CI: 1.28-33.82, NNH = 3), but not agitation, hypertension or affective switches. CONCLUSION: Our meta-analysis of randomized controlled trials of ketamine augmentation in the ECT setting suggests a lack of clinical efficacy, and an increased likelihood of confusion. Individuals for whom adequate seizures or therapeutic response cannot be obtained have not been studied using randomized controlled designs. Additional research is required to address the role of ketamine in this population.
Authors: Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Liam Trevithick; R Hamish McAllister-Williams; Andrew Blamire; Tim Branton; Ross Clark; Darragh Downey; Graham Dunn; Andrew Easton; Rebecca Elliott; Clare Ellwell; Katherine Hayden; Fiona Holland; Salman Karim; Jo Lowe; Colleen Loo; Rajesh Nair; Timothy Oakley; Antony Prakash; Parveen K Sharma; Stephen R Williams; Ian M Anderson Journal: BMC Psychiatry Date: 2015-10-21 Impact factor: 3.630
Authors: Ian M Anderson; Andrew Blamire; Tim Branton; Ross Clark; Darragh Downey; Graham Dunn; Andrew Easton; Rebecca Elliott; Clare Elwell; Katherine Hayden; Fiona Holland; Salman Karim; Colleen Loo; Jo Lowe; Rajesh Nair; Timothy Oakley; Antony Prakash; Parveen K Sharma; Stephen R Williams; R Hamish McAllister-Williams Journal: Lancet Psychiatry Date: 2017-03-27 Impact factor: 27.083
Authors: Gordon Fernie; James Currie; Jennifer S Perrin; Caroline A Stewart; Virginica Anderson; Daniel M Bennett; Steven Hay; Ian C Reid Journal: Br J Psychiatry Date: 2017-03-02 Impact factor: 9.319